Posts for Ticker ‘DVAX’

BioHealth Business Daily (BMRN, DVAX, SEPR, STEM, PCYC, OCLS)

biotech imageToday is an unusually active day for many emerging biotech stocks in the news and we are seeing significant moves in response. We have more detail on each with appropriate links through to more analysis and data at BioHealthInvestor.com or VSInvestor.com:

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is seeing exponential trading volume in stock and options after a 10% rise today.

Dynavax Technologies Corporation (NASDAQ: DVAX) is up over 50%after the FDA removed a clinical hold on its hepatitis treatment.

The fight over the Sepracor, Inc. (NASDAQ: SEPR) acquisition has now gone to the level of a class action status.  We noted the very low P/E and multiple valuations yesterday on this one.

StemCells, Inc. (NASDAQ: STEM) traded slightly higher on word that it will soon begin a study with the University of California, San Francisco Children’s Hospital using purified human neural stem cells as a possible treatment for Pelizaeus-Merzbacher Disease.

Pharmacyclics Inc. (NASDAQ: PCYC) was trading up on news that its right offering is oversubscribed.

Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) is trading higher on report that it has been assigned a Medicare HCPCS code for its recently introduced Microcyn Skin & Wound HydroGel.

JON C. OGG
SEPTEMBER 10, 2009

Posted on: September 10, 2009 – 1:38 pm in Biotech, Drug companies, HI/LOW, Trading Alert, , , , , ,

Biotech Implosion: Dynavax (DVAX)

Down_arrow_red_2Dynavax Technologies Corp. (NASDAQ: DVAX) is the latest biotech implosion as shares are down some 75% today.  The company gave an update on an FDA clinical hold on its investigational vaccine HEPLISAV with partner Merck & Co. (NYSE: MRK).

Read More »

Posted on: October 22, 2008 – 9:24 am in Biotech, FDA, ,

Top Pre-Market Analyst Downgrades (AMP, AAPL, DVAX, FCX, GMT, LNC, PCX, X)

Down_arrow_redThese are some of the top pre-market analyst downgrades from Wall Street this Wednesday morning:

  • Ameriprise Financial (AMP) Cut to Market Perform at KBW.
  • Apple (AAPL) Cut to Neutral at UBS.
  • Dynavax (DVAX) Cut to Perform at Oppenheimer.
  • Freeport-McMoran (FCX) Cut to Market Perform at FBR.
  • GATX (GMT) Cut to Neutral at Piper Jaffray.
  • Lincoln National (LNC) Cut to Market Perform at KBW.
  • Patriot Coal (PCX) Cut to Market Perform at FBR.
  • US Steel (X) Cut to Sell from Neutral at Goldman Sachs.

Jon C. Ogg
October 22, 2008

Posted on: October 22, 2008 – 6:52 am in Analyst Calls, , , , , , , ,

Top 10 Pre-Market Analyst Calls (AKAM, AEO, ARBA, BBI, CPWR, DVAX, FNSR, NCC, TOO, TXN)

These aren’t the only analyst calls this Monday morning, but these are the ones we are focusing on early this morning:

  • Akamai Tech (NASDAQ: AKAM) Cut to Hold from Buy at Citigroup.
  • American Eagle (NYSE: AEO) cut to Underperform at Friedman Billings.
  • Ariba (NASDAQ: ARBA) raised to Outperform at RBC Capital.
  • Blockbuster (NYSE: BBI) Added To Citigroup’s Top Picks list.
  • Compuware (NASDAQ: CPWR) Raised to Buy from Hold at Banc Of America.
  • Dynavax Technologies (NASDAQ: DVAX) cut to Peer Perform at Bear Stearns.
  • Finisar (NASDAQ: FNSR) Raised to Overweight at Thomas Weisel.
  • National City (NYSE: NCC) Raised to Buy from Hold at Citigroup.
  • Teekay Offshore (NYSE: TOO) raised to Outperform at Wachovia.
  • Texas Instruments (NYSE: TXN) Raised to Buy from Hold at Citigroup.

Jon C. Ogg
May 19, 2008

Jon Ogg produces and edits the "10 Stocks Under $10" newsletter and he does not own securities in the companies he covers.

Posted on: May 19, 2008 – 6:31 am in Analyst Calls, , , , , , , , , ,

The 52-Week Low Club (XRM)(MGI)(BGP)(DVAX)(NUVO)(SHFL)

Xerium Technologies (XRM) delays 10-K and risk of default. Falls to $1.16 from 52-week high of $9.20.

Moneygram (MGI) is taken out of one of the S&P indexes. Down to $1.62 from 52-week high of $30.67.

Borders Group (BGP) Bad time to be in the print business. Down to $6.98 from 52-week high of $24.15.

Dynavax Technologies (DVAX) FDA halts trials of a company drug. Falls to $2.07 from 52-week high of $6.55.

Nuvelo (NUVO) Cuts staff and announces failure of drug trial. Down to $.55 from 52-week high of $6.63.

Shuffle Master (SHFL) Post loss for quarter. Drops to $5.13 from 52-week high of $19.78.

Douglas A. McIntyre

Posted on: March 18, 2008 – 2:56 pm in HI/LOW, , , , , ,